ULBP3 and cancer: A cancer-associated mutation of IDH1 that generates the oncometabolite 2-hydroxyglutarate from cytoplasmic α-ketoglutarate (expected to diminish cytoplasmic citrate) has previously been shown to inhibit expression of the NKG2DLs ULBP1 and ULBP3 (84).